Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma

This trial is comparing a standard chemotherapy combination (CHOP) for T-cell lymphoma against the same treatment plus two additional drugs — tucidinostat (an epigenetic drug) and azacitidine — to see if the added drugs improve outcomes. **You may be eligible if...** - You are 18–70 years old - You have newly diagnosed peripheral T-cell lymphoma confirmed by pathology - Your general health is adequate (ECOG 0–2) - Your blood counts and organ function (heart, lungs, liver, kidneys) are within acceptable limits **You may NOT be eligible if...** - You have ALK-positive T-cell lymphoma or NK/T-cell nasal-type lymphoma - You have an uncontrolled active infection - You had a heart attack or unstable chest pain in the last 6 months - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.